Anuh Pharma shareholders seek reclassification to public category

Anuh Pharma Limited has disclosed that it has received requests from nine shareholders seeking reclassification from the promoter group to the public category. The intimation, dated May 19, 2026, was made in compliance with Regulation 31A of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The shareholders requesting the change collectively hold 9,49,988 equity shares, which accounts for 0.95% of the company's total paid-up share capital. The list of applicants includes individuals such as Kinjal Siddharth Jhaveri, who holds the largest portion among the applicants at 0.81%, and others like Nina Vijay Shah and Hemant Babubhai Choksi.

Details of Shareholders Seeking Reclassification

The following table outlines the shareholders who have submitted requests for reclassification along with their respective holdings:

Sr No. Name Number of Equity shares held % of shareholding 1. Madhurika Narendra Shah 12,000 0.01 2. Hemant Babubhai Choksi 24,000 0.02 3. Mukesh Kantilal Shah 14,400 0.01 4. Aruna Navnit Shah 5,040 0.01 5. Vikram Kirtilal Shah 200 0.00 6. Kiran Piyush Shah 15,388 0.02 7. Kinjal Siddharth Jhaveri 8,16,160 0.81 8. Nina Vijay Shah 60,000 0.06 9. Neela Pradeep Shah 2,800 0.003 TOTAL 9,49,988 0.95

Regulatory Compliance and Undertakings

The requests for reclassification are based on the rationale that these individuals are immediate relatives of promoters and are no longer involved in the day-to-day affairs or management of the company. They have stated that they do not exercise control over the company's affairs or possess special rights through formal or informal arrangements.

In their requests, the outgoing promoters have undertaken that they do not hold more than 10% of the total voting rights, are not represented on the Board of Directors, and do not act as key managerial personnel. They have also confirmed that they are not wilful defaulters or fugitive economic offenders, and there is no pending regulatory action against them.

Next Steps

The Board of Directors of anuh pharma will consider the requests at their ensuing meeting. Subsequently, the company will take appropriate steps to secure the necessary approvals from shareholders and stock exchanges. Once these approvals are received, the outgoing promoters will be reclassified as public shareholders.

Anuh Pharma Limited has received World Health Organization (WHO) Prequalification approval for its Active Pharmaceutical Ingredient (API), Amodiaquine Hydrochloride USP. The disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and was communicated to stock exchanges on 04 May 2026. This regulatory milestone reinforces the company's standing as a credible supplier for international anti-malarial programmes.

WHO Prequalification: A Key Regulatory Milestone

The WHO Prequalification programme is an internationally recognised certification that enables pharmaceutical manufacturers to demonstrate compliance with rigorous global quality, safety, and efficacy standards. Approval under this programme is particularly significant for APIs intended for use in public health programmes and procurement by international health agencies. The following table summarises the key details of the approved product:

Parameter: Details Product Name: Amodiaquine Hydrochloride USP (Amodiaquine HCl USP) Drug Category: Anti-Malarial API (Active Pharmaceutical Ingredient) Pharmacopoeial Standard: United States Pharmacopeia (USP) Approval Body: World Health Organization (WHO) – Prequalification Programme Approval Type: WHO Prequalification of Medicines Programme – Active Pharmaceutical Ingredient Applicable Market: International markets including WHO-procured and donor-funded programmes

About Amodiaquine Hydrochloride USP

Amodiaquine Hydrochloride is an essential medicine listed by the WHO and is widely used in combination therapies for the treatment of uncomplicated Plasmodium falciparum malaria. As an API, it forms the active core of finished anti-malarial formulations deployed across global health programmes. The WHO Prequalification of this product by Anuh Pharma validates the company's manufacturing capabilities against stringent international benchmarks and positions it as a preferred API supplier for global anti-malarial programmes, including those funded by donor agencies.

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.

As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation.

We plan to change that - a technology-led and artificial intelligence enabled platform built for super traders and long term investors.

Disclaimer:

The data and information provided on this website is for general informational and research purposes only. While we strive to ensure that the content is accurate, up-to-date, and reliable, this platform utilizes artificial intelligence (AI) tools to generate, curate, and summarize information. As such, the content may occasionally contain errors, omissions, or outdated information. All users are therefore advised to cross verify the source of the data and information.

This website does not constitute professional, legal, financial, medical, or any other form of licensed advice. Users are encouraged to independently verify any information before relying on it, especially for decisions that may have legal, financial, or personal consequences.

The views, analyses, and summaries presented on this platform may be generated or assisted by AI and do not necessarily reflect the opinions of the website owners, operators, editors, or affiliates.

We make no warranties or representations, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the information contained on this website. Any reliance you place on such information is strictly at your own risk.

This website may include links to third-party sources or content. We do not control or endorse the nature, accuracy, or availability of those external sites and are not responsible for any content or damages arising from their use.

By using this website, you acknowledge and agree that the use of AI-generated content involves inherent limitations, uncertainties and inaccuracies, and you accept full responsibility for how you interpret and use the information provided.

We reserve the right to modify, update, or remove content and this disclaimer at any time without prior notice.